Healthcare Realty Trust, Inc. Q3 FY2026 earnings call

Key managerial messages and operational highlights include:

• Leasing Momentum & Pricing Power:

  • Signed 1.5 million square feet of leases, including 430,000 square feet of new business.
  • Achieved cash leasing spreads of 8.6%, the highest level in nearly a decade, driven by rising tenant demand and constrained new supply.
  • Retention rates remained strong at approximately 88-90%, supported by high build-out costs for tenants and limited development alternatives.
  • Escalators are now viewed as a floor of 3%, with some deals achieving closer to 4%.

• Strategic Focus on Outpatient Care:

  • The shift from inpatient to outpatient settings is accelerating, aided by changes in the "inpatient only" rule and health systems acquiring outpatient surgery centers (e.g., Ascension St. Thomas, Bon Secours).
  • New medical outpatient construction remains muted due to elevated financing and construction costs, favoring existing operators like Healthcare Realty.

• Capital Allocation Discipline:

  • Repurchased $75 million of stock during Q3 (bringing YTD repurchases to $250 million), citing a significant discount to NAV as a driver for accretive buybacks.
  • Acquired eight medical office buildings via joint ventures with KKR for a total of $338 million ($67 million at share), targeting mid-7% initial cash yields.
  • Monetized over $200 million of assets YTD, with an average disposition yield expected in the mid-5% range.

• Portfolio Optimization & Fundamentals:

  • Completed $1.1 billion of debt refinancing at a blended rate of ~4%, locking in low fixed rates.
  • Leverage decreased slightly to 5.5x, consistent with mid-5x targets.
  • Lease Internal Rate of Return (IRR) has improved by nearly 3,000 basis points since implementing the new economics-driven leasing model.
  • Weighted Average Lease Term increased from 50 months to 65 months through proactive lease renewals.

The company reported Normalized Funds From Operations (FFO) of $0.42 per share and Same-Store Net Operating Income (NOI) growth of 5.1%. While specific revenue breakdowns by product segment are not detailed in the transcript, the firm operates as a pure-play Medical Office Building (MOB) REIT. The total portfolio occupancy improved to 93.1%, with the redevelopment sub-segment reaching 72% leased. Cash leasing spreads were recorded at 8.6%, reflecting strong pricing power across the core MOB assets.

Management raised full-year guidance for the third time this year, reflecting strong operating momentum:

• Normalized FFO Per Share: Raised to a range of $1.65 – $1.67 (midpoint of $1.66), an increase of $0.02 from previous guidance.
• Same-Store Cash NOI Growth: Raised to a range of 5.0% – 5.25%, an increase of 75 basis points at the bottom end and 25 basis points at the top end.
• Disposition Guidance: Increased by $85 million to reflect incremental share repurchases and JV acquisitions funded by sales.
• Q4 Outlook: Management noted that while fundamentals remain strong, Q4 may see slightly less absorption compared to prior quarters, though they aim to hit the high end of the guidance range.

Discussion of risks and operational factors includes:

• Interest Rate Sensitivity: Higher interest rates have weighed on real estate stock valuations and impacted cap rates for weaker, value-add assets reliant on leverage, though core/core-plus assets have held steady.
• Development Costs: Elevated construction and debt financing costs continue to suppress new MOB supply, which benefits incumbents but increases costs for any development activity.
• Market Volatility: Transaction volumes may slow as buyers and sellers wait for interest rate stability, potentially impacting the pace of acquisitions or dispositions.
• Tenant Concentration: A significant portion of leasing activity involves large health systems; while relationships are strong, negotiations are complex and require careful management to maintain favorable terms.

Q: Analyst asked if the record 8.6% cash leasing spread is repeatable long-term and how much same-store NOI growth is driven by occupancy vs. pricing. / A: CEO Pete Scott stated that while 8.6% was boosted by specific large deals (like Ascension), the underlying trend supports maintaining spreads above 5% historically. He emphasized that fundamentals have structurally improved, allowing the company to push pricing power without capping potential upside, noting that occupancy has risen from 89% to 93% year-over-year alongside these pricing gains.

Q: Analyst asked about the transaction market dynamics, specifically if cap rates have repriced given higher rates and if private buyers are pulling back. / A: Scott clarified that core cap rates (5.5%-6%) and core-plus rates (6%-6.5%) have remained stable because private buyers are less reliant on debt. Repricing is primarily visible in weaker, value-add assets dependent on leverage. He noted that transaction volumes might slow temporarily due to market uncertainty but expect quick recovery if rates stabilize.

Q: Analyst inquired about the impact of site-neutral payment policies and health system consolidation on outpatient demand and tenant leverage. / A: Scott confirmed the shift to outpatient care is accelerating, citing health systems buying outpatient surgery networks. Regarding consolidation, he argued it creates synergies and expansion rather than space reduction/overlap, strengthening tenant profitability and negotiation positions. This dynamic allows Healthcare Realty to extract better lease terms despite the size of health system partners.

Q: Analyst asked about the sources of FFO vs. FAD divergence, specifically regarding straight-line rent adjustments and lease expiration schedules. / A: CFO Dan Gabbay and CEO Scott explained that the company proactively accelerated large lease renewals to extend the weighted average lease term (from 50 to 65 months). This strategy provides an immediate FFO benefit, with FAD growth expected to catch up subsequently. They view lease expirations as opportunities for re-leasing at higher spreads rather than risks.

Q: Analyst asked about future capital allocation priorities between Joint Venture acquisitions and stock buybacks, and whether development funding is an option. / A: Scott indicated the company will flexibly shift between buybacks and JVs based on valuation disconnects. With the stock trading at a discount to NAV, buybacks remain highly accretive. He highlighted a strategic intent to increase NOI exposure to JVs with KKR, viewing the platform as a partner for capital entering the sector, while noting that direct development is currently unattractive due to high costs and pre-leasing requirements.